FDA panel to review Edwards SAPIEN valve next month

Edwards Lifesciences has announced that an FDA advisory panel is scheduled to review the company's PMA application for its Edwards SAPIEN transcatheter heart valve on July 20. Edwards submitted the application last fall based on data from the inoperable cohort (Cohort B) of The PARTNER Trial, for approval of this therapy in the treatment of inoperable patients with severe aortic stenosis.
Edwards Lifesciences release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.